2010-17785. Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 27 New Drug Applications and 58 Abbreviated New Drug Applications
-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) is withdrawing approval of 27 new drug applications (NDAs) and 58 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
DATES:
Effective Date: August 20, 2010.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6366, Silver Spring, MD 20993-0002, 301-796-3601.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
The holders of the applications listed in table 1 of this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications pursuant to the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.
Table 1.
Application No. Drug Applicant NDA 6-008 Mesantoin (mephenytoin) Tablets Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, NJ 07936-1080 NDA 9-000 Cafergot (ergotamine tartrate and caffeine) Suppository, 1 milligram (mg)/100 mg and 2 mg/100 mg Do. NDA 9-561 Hypaque (diatrizoate sodium) GE Healthcare, Inc., 101 Carnegie Center, Princeton, NJ 08540 NDA 9-658 Hydrocortisone Tablets Smith, Miller and Patch, Inc., Division of Cooper Vision, Inc., c/o Cooper Laboratories, Inc., 455 E. Middlefied Rd., Mountain View, CA 94043 NDA 9-942 Deltra (prednisone) Tablets Merck & Co., Inc., P.O. Box 4, BLA-20, West Point, PA 19486-0004 NDA 10-051 Hydeltra (prednisolone) Tablets Do. NDA 10-255 Meticortelone (prednisolone acetate) Injection and Suspension Schering Corp., Galloping Hill Rd., Kenilworth, NJ 07033 NDA 12-885 Winstrol (stanozolol) Tablets, 2 mg Lundbeck, Inc., Four Parkway North, Deerfield, IL 60015 NDA 13-428 Valpin (anisotropine methylbromide) Tablets Endo Pharmaceuticals, 100 Endo Blvd., Chadds Ford, PA 19317 Start Printed Page 42456 NDA 16-023 Symmetrel (amantadine hydrochloride (HCl) USP) Syrup Do. NDA 16-119 Teslac (testolactone) Injection, 100 mg/milliliter (mL) Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543-4000 NDA 16-403 Hypaque-Cysto (diatrizoate meglumine) and Hypaque (diatrizoate meglumine) GE Healthcare, Inc. NDA 16-636 Narcar (naloxone HCl) Injection Endo Pharmaceuticals NDA 16-769 Urispas (flavoxate HCl) Tablets, 100 mg Ortho-McNeil-Janssen Pharmaceutical, Inc., 1000 U.S. Highway 202, P.O. Box 3000, Raritan, NJ 08869-0602 NDA 17-022 Methotrexate Tablets Lederle Laboratories, A Division of American Cyanamid Co., 401 N. Middletown Rd., Pearl River, NY 10965 NDA 17-118 Symmetrel (amantadine HCl USP) Syrup Endo Pharmaceuticals NDA 17-255 MPI DTPA Chelate multidose (kit for the preparation of technetium Tc-99m pentetate injection) Medi-Physics, Inc., d/b/a GE Healthcare, Inc., 101 Carnegie Center, Princeton, NJ 08540 NDA 17-264 Technetium Tc-99m pentetate kit Do. NDA 17-559 Proventil (albuterol USP) Inhalation Aerosol Schering Corp. NDA 17-984 Valcaps (diazepam) Capsules Hoffmann-LaRoche, Inc., Roche Pharmaceuticals, 340 Kingsland St., Nutley, NJ 07110-1199 NDA 18-101 Symmetrel (amantadine HCl USP) Tablets Endo Pharmaceuticals NDA 18-445 Dolobid (diflunisal) Tablets, 250 mg and 500 mg Merck & Co., Inc. ANDA 18-551 Potassium Iodide Oral Solution USP, 1 gram (g)/mL Roxane Laboratories, Inc., 1809 Wilson Rd., Columbus, OH 43228 NDA 18-706 Hydergine LC (ergoloid mesylates) Capsules Novartis Pharmaceuticals Corp. NDA 18-746 Vasocon-A (antazoline phosphate, 0.5% and naphazoline HCl, 0.05%) Ophthalmic Solution Do. ANDA 18-750 Furosemide Tablets, 40 mg Sandoz, Inc., 4700 Sandoz Dr., Wilson, NC 27893 NDA 19-309 Vasotec (enalaprilat) Injection Biovail Laboratories International SRL, c/o Biovail Technologies Ltd., 700 Route 202/206 North, Bridgewater, NJ 08807 NDA 21-007 Agenerase (amprenavir), 50 mg and 150 mg GlaxoSmithKline, One Franklin Plaza, 200 North 16th St., Philadelphia, PA 19102 NDA 21-039 Agenerase (amprenavir) Oral Solution, 15 mg/mL Do. ANDA 40-149 Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/500 mg and 7.5 mg/750 mg Sandoz, Inc. ANDA 40-312 Innofem (estradiol tablets USP), 0.5 mg, 1 mg, and 2 mg Novo Nordisk, Inc., 100 College Rd. West, Princeton, NJ 08540 ANDA 60-568 Urobiotic (oxytetracycline HCl, sulfamethizole, phenazopyridine HCl) Capsules Pfizer Inc., 235 East 42nd St., New York, NY 10017 ANDA 61-016 Terra-Cortril (hydrocortisone acetate and oxytetracycline HCl) Do. ANDA 61-410 Veetids (penicillin V potassium for Oral Solution USP), 125 mg/5 mL and 250 mg/5 mL Apothecon, c/o Bristol-Myers Squibb, P.O. Box 4000, Princeton, NJ 08543 ANDA 61-471 Tetracycline HCl Capsules, 250 mg Sandoz, Inc. ANDA 61-781 Erythromycin StearateTablets, 250 mg Do. ANDA 61-965 Nystatin Vaginal Tablets, 100,000 Units Do. ANDA 62-014 Oxytetracycline Capsules, 250 mg Do. ANDA 62-065 Nystatin Tablets, 500,000 Units Do. Start Printed Page 42457 ANDA 62-590 Kefurox (cefuroxime for injection USP), 750 mg/vial and 1.5 g/vial Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285 ANDA 62-592 Kefurox (cefuroxime for injection USP), 750 mg/vial and 1.5 g/vial Do. ANDA 64-033 Cefazolin Sodium ADD-Vantage Powder for Injection Solution GlaxoSmithKline, One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101-7929 ANDA 65-210 Clarithromycin Extended-Release Tablets, 1,000 mg Ranbaxy, Inc., U.S. Agent for Ranbaxy Laboratories Limited, 600 College Rd. East, Princeton, NJ 08540 ANDA 73-696 Nitrofurantoin Capsules USP, 25 mg, 50 mg, and 100 mg Watson Laboratories, Inc., P.O. Box 450 39 Mt. Ebo Rd. South, Brewster, NY 10509 ANDA 74-648 Lorazepam Oral Solution, 0.5 mg/5 mL Roxane Laboratories, Inc. ANDA 74-764 Ranitidine Injection USP Bedford Laboratories, A division of Ben Venue Laboratories, Inc., 300 Northfield Rd., Bedford, OH 44146 ANDA 75-170 Butorphanlol Tartrate Injection USP, 1 mg/mL and 2 mg/mL Hospira, Inc., 275 N. Field Dr., Dept. 0389, Bldg. H2, Lake Forest, IL 60045-5046 ANDA 76-027 Tamoxifen Citrate Tablets USP, 10 mg and 20 mg Roxane Laboratories, Inc. ANDA 76-605 Gabapentin Tablets USP, 600 mg and 800 mg Do. ANDA 76-643 Carbidopa and Levodopa Tablets for Oral Suspension, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg Do. ANDA 76-663 Carbidopa and Levodopa Extended-Release Tablets, 50 mg/200 mg KV Pharmaceutical Co., 2503 South Hanley Rd., St. Louis, MO 63144 ANDA 77-366 Glimepiride Tablets USP, 3 mg and 6 mg Ranbaxy Inc. ANDA 81-096 Acetaminophen, Aspirin, and Codeine Phosphate Capsules, 150 mg/180 mg/30 mg Mikart, Inc., 1750 Chattahoochee Ave., NW, Atlanta, GA 30318 ANDA 81-097 Acetaminophen, Aspirin, and Codeine Phosphate Capsules, 150 mg/180 mg/60 mg Do. ANDA 81-226 Hydrocodone Bitartrate and Acetaminophen Oral Solution, 5 mg/500 mg/15 mL Do. ANDA 83-902 Dexedrine (dextroamphetamine sulfate), 5 mg/mL GlaxoSmithKline, Research Triangle Park, NC 27709-3398 ANDA 84-353 Bethanechol Chloride Tablets, 5 mg Do. ANDA 84-378 Bethanechol Chloride Tablets, 10 mg (Blue) Do. ANDA 84-379 Bethanechol Chloride Tablets, 10 mg (Pink) Do. ANDA 84-383 Bethanechol Chloride Tablets, 25 mg (Yellow) Do. ANDA 84-384 Bethanechol Chloride Tablets, 25 mg Do. ANDA 84-617 Hydralazine HCl and Reserpine Tablets, 25 mg/0.1 mg Do. ANDA 84-773 Prednisolone Tablets, 5 mg Do. ANDA 84-774 Prednisone Tablets, 5 mg Do. ANDA 84-869 Imipramine HCl Tablets, 25 mg Do. ANDA 84-876 Hydrochlorothiazide, Reserpine, and Hydralazine HCl Tablets, 15 mg/0.1 mg/25 mg Do. ANDA 84-935 Dexedrine (dextroamphetamine sulfate) Tablets GlaxoSmithKline, Research Triangle Park, NC 27709-3398 ANDA 84-956 Hydralazine HCl Tablets, 25 mg Sandoz, Inc. Start Printed Page 42458 ANDA 85-088 Hydralazine HCl Tablets, 50 mg Do. ANDA 85-146 Promethazine HCl Tablets, 25 mg and 50 mg Do. ANDA 85-934 Butabarbital Sodium Tablets, 30 mg Do. ANDA 85-938 Butabarbital Sodium Tablets, 15 mg Do. ANDA 86-171 Trichlormethiazide Tablets, 4 mg Do. ANDA 86-505 Hypaque-76 (diatrizoate meglumine and diatrizoate sodium injection USP) GE Healthcare, Inc. ANDA 87-118 Chlorthalidone Tablets, 50 mg Sadoz, Inc. ANDA 87-282 Methocarbamol Tablets, 750 mg Do. ANDA 87-283 Methocarbamol Tablets, 500 mg Do. ANDA 87-449 Theophylline Oral Solution, 80 mg/15 mL Roxane Laboratories, Inc. ANDA 87-462 Theophylline Extended-Release Capsules, 260 mg Sandoz, Inc. ANDA 88-157 Chlorpromazine HCl Intensol (chlorpromazine HCl oral concentrate USP), 30 mg/mL Roxane Laboratories, Inc. ANDA 88-158 Chlorpromazine HCl Intensol (chlorpromazine HCl oral concentrate USP), 100 mg/mL Do. ANDA 88-193 Triprolidine HCl and Pseudoephedrine HCl Tablets, 2.5 mg/60 mg Sandoz, Inc. ANDA 88-587 Hydrochlorothiazide Oral Solution Roxane Laboratories, Inc. ANDA 89-127 Mepro-Aspirin (aspirin and meprobamate) Tablets, 325 mg/200 mg Sandoz, Inc. ANDA 89-508 Fluorouracil Injection USP, 50 mg/mL Bedford Laboratories Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research, by the Commissioner, approval of the applications listed in table 1 in this document, and all amendments and supplements thereto, is hereby withdrawn, effective August 20, 2010. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the act (21 U.S.C. 331(a) and (d)). Drug products that are listed in table 1 in this document that are in inventory on the date that this notice becomes effective (see the DATES section) may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
Start SignatureDated: June 15, 2010.
Douglas C. Throckmorton,
Deputy Director, Center for Drug Evaluation and Research.
[FR Doc. 2010-17785 Filed 7-20-10; 8:45 am]
BILLING CODE 4160-01-S
Document Information
- Comments Received:
- 0 Comments
- Published:
- 07/21/2010
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 2010-17785
- Pages:
- 42455-42458 (4 pages)
- Docket Numbers:
- Docket No. FDA-2010-N-0318
- PDF File:
- 2010-17785.pdf